文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

弥漫性大B细胞淋巴瘤的靶向治疗和免疫治疗

Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma.

作者信息

Chaudhari Jahnavi, Shah Nikesh N

机构信息

Department of Internal Medicine, HCA Florida Oak Hill Hospital, Brooksville, FL 34613, USA.

USF Health Morsani College of Medicine, Tampa, FL 33602, USA.

出版信息

Cancers (Basel). 2025 Jul 30;17(15):2517. doi: 10.3390/cancers17152517.

DOI:10.3390/cancers17152517
PMID:40805213
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12345741/
Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL) [...].

摘要

弥漫性大B细胞淋巴瘤（DLBCL）是最常见的侵袭性非霍奇金淋巴瘤（NHL）[...]。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4999/12345741/30db1235fa23/cancers-17-02517-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4999/12345741/30db1235fa23/cancers-17-02517-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4999/12345741/30db1235fa23/cancers-17-02517-g001.jpg

相似文献

[1]
Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma.

Cancers (Basel). 2025-7-30

[2]
Bispecific Antibodies and Antibody-Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma.

Cancers (Basel). 2025-7-26

[3]
Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma.

Expert Opin Biol Ther. 2021-11

[4]
Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody.

Cureus. 2022-12-31

[5]
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

Lancet Oncol. 2015-4-27

[6]
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events.

Leuk Lymphoma. 2025-6-30

[7]
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.

J Cancer Res Clin Oncol. 2022-1

[8]
Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.

Expert Rev Anticancer Ther. 2021-12

[9]
Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma.

Eur J Clin Pharmacol. 2022-5

[10]
Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States.

J Med Econ. 2025-12

本文引用的文献

[1]
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.

Blood. 2025-7-15

[2]
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.

Br J Haematol. 2025-7

[3]
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma.

Blood Cancer J. 2025-4-23

[4]
Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP.

Blood Adv. 2025-7-22

[5]
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study.

Nat Cancer. 2025-4-3

[6]
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.

Nat Cancer. 2025-3

[7]
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.

Blood. 2025-4-10

[8]
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.

Blood. 2025-4-3

[9]
Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study.

Cancer. 2025-1-1

[10]
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.

Lancet. 2024-11-16

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索